News

Webcast Image Webcast
Q4 2023 IRIDEX Earnings Conference Call
 03/26/24 at 5:00 PM EDT

Keyword Search

Date Title Teaser
12/22/20
 Summary ToggleIRIDEX Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelines Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma MOUNTAIN VIEW, Calif. , Dec.
11/09/20
 Summary ToggleIRIDEX Announces Third Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020 . Third Quarter Summary Total revenue of $8.8 million , a decline of 17% versus $10.7 million in the prior year period, and an
11/03/20
 Summary ToggleIRIDEX to Present at the 2020 Stifel Virtual Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference . David I. Bruce , IRIDEX’s President and Chief Executive Officer, is scheduled to present on Tuesday,
10/26/20
 Summary ToggleIRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020 MOUNTAIN VIEW, Calif. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020 . The Company’s management team will host a corresponding
08/06/20
 Summary ToggleIRIDEX Announces Second Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020 . Second Quarter Summary Total revenue declined 40% to $6.2 million versus $10.4 million in the prior year period Cost control
07/23/20
 Summary ToggleIRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020 MOUNTAIN VIEW, Calif. , July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of trading on Thursday, August 6, 2020 .  The Company’s management team will host a corresponding
05/11/20
 Summary ToggleIRIDEX Announces First Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 28, 2020 . Commenting on the recently completed quarter and the business environment created by the COVID-19 pandemic, David I.
04/28/20
 Summary ToggleIRIDEX to Report First Quarter 2020 Financial Results on May 11, 2020 MOUNTAIN VIEW, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020 . The Company’s management team will host a corresponding
04/21/20
 Summary ToggleIRIDEX Announces the Appointment of Doris Engibous to its Board of Directors MOUNTAIN VIEW, Calif. , April 21, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective
03/30/20
 Summary ToggleIRIDEX ANNOUNCES RETIREMENT OF VP FINANCE Names Prior CFO/COO as Interim CFO MOUNTAIN VIEW, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Romeo Dizon has retired from his
03/12/20
 Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2019 Financial Results MOUNTAIN VIEW, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28, 2019 . Fourth Quarter Highlights Cyclo G6® product family revenue grew 18% year-over-year to $3.7 million , or 31% of total revenue
02/28/20
 Summary ToggleIRIDEX to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 MOUNTAIN VIEW, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year of 2019 after the close of trading on Thursday, March 12, 2020 .  The Company’s management team will host a
02/26/20
 Summary ToggleIRIDEX Launches Revised MicroPulse P3® Device for Glaucoma MOUNTAIN VIEW, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today the introduction of the second generation of the MicroPulse P3 ® Device,
01/13/20
 Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2019 MOUNTAIN VIEW, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 28, 2019 . Highlights Total revenue for the fourth quarter of 2019 expected to be $11.6 -